Skip to content

Semaglutide vs Tirzepatide: side-by-side comparison

GLP-1 Agonist

Ozempic · Wegovy · Rybelsus

A GLP-1 receptor agonist used for weight loss, appetite suppression, and type 2 diabetes management. Originally developed and approved as Ozempic for diabetes, the same drug is now FDA-approved as Wegovy for chronic weight management (injectable and, since December 2025, an oral tablet) and as Rybelsus for oral diabetes treatment. Also carries FDA approvals for reducing major cardiovascular events (SELECT trial) and slowing chronic kidney disease progression in type 2 diabetics (FLOW trial).

3.0/10 natty
Full breakdown →
VS
GLP-1 Agonist

Mounjaro · Zepbound · LY3298176

A first-in-class dual GLP-1/GIP receptor agonist (sometimes called a "twincretin"). This 39-amino acid synthetic peptide activates both incretin receptors, producing superior weight loss and glycemic control compared to GLP-1-only agonists like semaglutide. The most effective FDA-approved pharmaceutical weight loss agent currently on the market (investigational triple agonists like retatrutide show larger effects in trials but are not yet approved).

3.0/10 natty
Full breakdown →

3 / 10 natty scale / 3

Same lane

Both sit in the same class and are run for cutting, health. This is a like-for-like comparison: read the gaps as real trade-offs.

The tape

Core ratings

The same three rulers every entry on the site is scored with, read head to head.

SemaglutideTirzepatide
3.0

Natty scale

1 natural · 10 heavy

3.0
4.0

Effectiveness

Documented effect · of 5Δ1

5.0
3.0

Side-effect severity

Documented burden · of 5Δ0.5

2.5

Cost side

Body-load fingerprint

Where each one actually lands its strain, on the calculator's thirteen channels. Tap a row for what it means and which labs track it.

SemaglutideTirzepatide

Organ strain

Systemic

Injection & site care

Bars show strain at each one's typical protocol, not your dose. ≈ marks values inferred from side-effect data or category rather than hand-graded. For your numbers, run the calculator.

Logistics

The vitals

SemaglutideTirzepatide
GLP-1 Agonist
Classmatch
GLP-1 Agonist
Subcutaneous
Routematch
Subcutaneous
0.25-2.4 mg/weekOnce weekly subcutaneous injection
Typical dose
2.5-15 mg/weekOnce weekly subcutaneous injection
~7 days (165-184 hours)
Half-life
~5 days (120 hours)
12-52 weeks
Typical runmatch
12-52 weeks
Prescription only
Legal statusmatch
Prescription only
Not prohibited
WADAmatch
Not prohibited

Benefit side

What each is for

Shared goals carry both dots; a goal with one dot belongs to that side alone.

SemaglutideTirzepatide
CuttingHealth

Run for

Appetite SuppressionDramatically reduces hunger and food cravings.
Weight LossPromotes significant weight loss through reduced caloric intake.
Metabolic HealthImproves insulin sensitivity and blood sugar control.

Documented upside

  • Significant appetite reduction
  • Substantial weight loss (~15% at 68 weeks in STEP 1)
  • Improved blood sugar control
  • Once-weekly dosing (injectable forms)
  • FDA-approved with extensive safety data
+2 more on the full page

Run for

Weight LossProduces up to ~21% body weight loss (intention-to-treat) at the 15mg dose in SURMOUNT-1, one of the largest effects of any approved pharmaceutical intervention. Among participants who stayed on treatment throughout the trial, average weight loss reached ~22.5% (52 lbs) at the highest dose.
Type 2 Diabetes ManagementProvides superior glycemic control with significant HbA1c reductions; patients who lose substantial weight can see blood sugar return to normal (remission) without medication.
Metabolic HealthImproves multiple metabolic markers including lipids, blood pressure, and inflammatory markers.
Body RecompositionPrimarily a fat loss agent: roughly 75% of weight lost is fat and 25% is lean mass. A 2025 DXA sub-study of SURMOUNT-1 found this ratio was essentially the same in the diet-only placebo arm, so tirzepatide does not spare muscle better than dieting alone; it simply causes more total weight (and more total muscle) to be lost.

Documented upside

  • Most effective FDA-approved weight loss medication available (up to ~21% body weight reduction, intention-to-treat, at the 15mg dose)
  • Superior to semaglutide in head-to-head trials (SURMOUNT-5: 20.2% vs 13.7% weight loss at week 72, a ~6.5 percentage-point difference)
  • Significant improvements in insulin sensitivity and glycemic control
  • Non-inferior to dulaglutide (another GLP-1 drug) for major cardiovascular events in the SURPASS-CVOT trial, with a favorable trend that did not reach statistical superiority
  • Once-weekly dosing for convenience
+3 more on the full page

The downsides

Side effects, aligned

Each entry's documented side effects, sorted onto the same body systems so the gaps and the overlaps are visible. Tap any effect for the detail.

SemaglutideTirzepatide

None documented

Blood sugar

None documented

Heart

None documented

Injection site
Other documented effects

The exit

Hormonal fallout & recovery

What each does to your own hormone axis while on, and what leaving it costs.

SemaglutideTirzepatide
Not required
PCT
Not required
While-on only
What sticks
While-on only

Semaglutide

Not hormonal. No PCT required.

Tirzepatide

Not hormone-based. No PCT required. However, weight regain is common after discontinuation - lifestyle modifications should be maintained.

Read-out

How they separate

  1. 01

    Enhancement

    They land at almost the same point on the natty scale (3/10 vs 3/10): a similar distance beyond natural.

  2. 02

    Side-effect bill

    Semaglutide's documented side-effect severity is heavier (3/5 vs 2.5/5). The body-load fingerprint above shows where that weight actually lands.

  3. 03

    Coming off

    Neither requires PCT: both leave the natural testosterone axis running.

Generated from each entry's data file. Descriptive, not a recommendation; nothing here is medical advice.

Full breakdownSemaglutide→Full breakdownTirzepatide→

More matchups

Semaglutide vs LiraglutideSemaglutide vs CagrilintideTirzepatide vs LiraglutideTirzepatide vs Cagrilintide